| Id |
Subject |
Object |
Predicate |
Lexical cue |
| T254 |
0-4 |
Sentence |
denotes |
3.3. |
| T255 |
5-25 |
Sentence |
denotes |
Atazanavir (Reyataz) |
| T256 |
26-136 |
Sentence |
denotes |
Atazanavir (Figure 6) is another antiretroviral drug that competitively inhibits the HIV-1 aspartate protease. |
| T257 |
137-180 |
Sentence |
denotes |
Atazanavir was approved in 2003 by the U.S. |
| T258 |
181-327 |
Sentence |
denotes |
FDA and usually prescribed in combination with the pharmacokinetic booster cobicistat (combination is being marketed under the name Evotaz; 2015). |
| T259 |
328-590 |
Sentence |
denotes |
Currently, it is being evaluated alone (NCT04468087; n = 189) or in combination with NA-831 (neuroprotective agent; traneurocin) or dexamethasone for the treatment of COVID-19 infection (NCT04452565; n = 525) or with nitazoxanide/ritonavir (NCT04459286; n = 98). |
| T260 |
591-778 |
Sentence |
denotes |
The drug alone or in combination with ritonavir demonstrated in vitro activity against SARS-CoV-2 in Vero E6 cells, human epithelial pulmonary cells (A549), and human monocytes [109,110]. |
| T261 |
779-849 |
Sentence |
denotes |
In these studies, atazanavir has been identified as inhibitor of Mpro. |
| T262 |
850-975 |
Sentence |
denotes |
The drug and its combination have been projected to be 10-fold more potent than lopinavir and its combination with ritonavir. |
| T263 |
976-1061 |
Sentence |
denotes |
The drug also inhibited the virus-induced enhancement of IL-6 and TNF-α levels [109]. |
| T264 |
1062-1218 |
Sentence |
denotes |
In a separate computational study, atazanavir was reported as a potential inhibitor of SARS-CoV-2 helicase, a viral enzyme that unwinds nucleic acids [111]. |
